These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20105406)

  • 1. Data Monitoring Committees.
    Novack GD
    Ocul Surf; 2010 Jan; 8(1):40-3. PubMed ID: 20105406
    [No Abstract]   [Full Text] [Related]  

  • 2. Data monitoring committees and randomized clinical trials.
    Trachtman H; Caplan AL
    Kidney Int; 2019 Apr; 95(4):992. PubMed ID: 30904070
    [No Abstract]   [Full Text] [Related]  

  • 3. Stopping rules, interim analyses and data monitoring committees.
    Ashby D; Machin D
    Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
    [No Abstract]   [Full Text] [Related]  

  • 4. Striding forward or getting too big for their boots? The developing role of data monitoring committees in clinical trials.
    Tharmanathan P; Calvert MJ; Freemantle N
    J Clin Pharm Ther; 2006 Apr; 31(2):111-8. PubMed ID: 16635044
    [No Abstract]   [Full Text] [Related]  

  • 5. Risks in Randomized Controlled Trials: Role of Interim Analysis and Data Monitoring Committee.
    Naqvi HA
    J Coll Physicians Surg Pak; 2015 Aug; 25(8):557-9. PubMed ID: 26305298
    [No Abstract]   [Full Text] [Related]  

  • 6. University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (afternoon panel session).
    Dickersin K; Dixon D; Ferris F; Goldberg J; Kimmel S; Lachin J
    Clin Trials; 2018 Aug; 15(4):366-385. PubMed ID: 30021497
    [No Abstract]   [Full Text] [Related]  

  • 7. Data monitoring and safety committees and their operations.
    Rouse DJ
    Obstet Gynecol Surv; 2003 May; 58(5):329-36. PubMed ID: 12719675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Data monitoring committees and stopping trials-Giving participants a voice.
    Trachtman H; Caplan A
    Contemp Clin Trials; 2018 May; 68():146. PubMed ID: 29567282
    [No Abstract]   [Full Text] [Related]  

  • 9. Data monitoring (and safety) committees--what are they and why do we need them? Primary Care Alliance for Clinical Trials (PACT) Network.
    Pirotta M; Chondros P;
    Aust Fam Physician; 2004 Nov; 33(11):950-1, 956. PubMed ID: 15584339
    [No Abstract]   [Full Text] [Related]  

  • 10. Ethical issues arising when interim data in clinical trials is restricted to independent data monitoring committees.
    Wells RJ; Gartside PS; McHenry CL
    IRB; 2000 Jan; 22(1):7-11. PubMed ID: 12546010
    [No Abstract]   [Full Text] [Related]  

  • 11. Interim monitoring of efficacy data is important and appropriate.
    Sydes MR; Parmar MK
    J Clin Epidemiol; 2008 Mar; 61(3):203-4. PubMed ID: 18226741
    [No Abstract]   [Full Text] [Related]  

  • 12. Continuous safety monitoring for randomized controlled clinical trials.
    Piller LB; Silverman MH; Ball G
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S1. PubMed ID: 21458597
    [No Abstract]   [Full Text] [Related]  

  • 13. Challenges to Data Monitoring Committees When Regulatory Authorities Intervene.
    Swedberg K; Borer JS; Pitt B; Pocock S; Rouleau J
    N Engl J Med; 2016 Apr; 374(16):1580-4. PubMed ID: 27043879
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized trials in oncology stopped early for benefit.
    Wilcox RA; Djulbegovic B; Moffitt HL; Guyatt GH; Montori VM
    J Clin Oncol; 2008 Jan; 26(1):18-9. PubMed ID: 18165635
    [No Abstract]   [Full Text] [Related]  

  • 15. Interim analysis in randomized trials: DAMOCLES' sword?
    Besselink MG; van der Graaf Y; Gooszen HG
    J Clin Epidemiol; 2010 Apr; 63(4):353-4. PubMed ID: 19959333
    [No Abstract]   [Full Text] [Related]  

  • 16. Keeping patients safe while avoiding bias in randomised trials.
    Freemantle N; Van de Werf F
    BMJ; 2012 May; 344():e3297. PubMed ID: 22586233
    [No Abstract]   [Full Text] [Related]  

  • 17. Novartis Reply to the ATMOSPHERE Data Monitoring Committee.
    Tougas G; Aftring RP
    N Engl J Med; 2016 Apr; 374(16):1586-7. PubMed ID: 27043488
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulatory Reply to the ATMOSPHERE Data Monitoring Committee.
    Salmonson T; Janssen H; Sudhop T; Stahl E
    N Engl J Med; 2016 Apr; 374(16):1585-6. PubMed ID: 27043362
    [No Abstract]   [Full Text] [Related]  

  • 19. The statistician and the data monitoring committee.
    D'Agostino RB
    Stat Med; 2004 May; 23(10):1501-2. PubMed ID: 15122726
    [No Abstract]   [Full Text] [Related]  

  • 20. Early viewing of noninferiority trials in progress.
    Dignam JJ
    J Clin Oncol; 2005 Aug; 23(24):5461-3. PubMed ID: 16027438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.